Zydus receives approval from COFEPRIS of Mexico to market ‘Bhava’ to treat various cancers

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Mylab receives approval for HPV RT-PCR test for cervical cancers

‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.

Next-gen immunotherapy drug shows promise in several advanced-stage cancers

Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells

Biological Dynamics study demonstrates detection of early-stage cancers

In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis

Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers

To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline

Research demonstrates Hoth Therapeutics HT-KIT for mast cell cancers reduces size and spread

Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival